Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Monocytes educated by cancer-associated fibroblasts secrete exosomal miR-181a to activate AKT signaling in breast cancer cells.

Tytuł:
Monocytes educated by cancer-associated fibroblasts secrete exosomal miR-181a to activate AKT signaling in breast cancer cells.
Autorzy:
Pakravan K; Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, P.O. Box: 14115-154, Tehran, Iran.
Mossahebi-Mohammadi M; Department of Hematology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Ghazimoradi MH; Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, P.O. Box: 14115-154, Tehran, Iran.
Cho WC; Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong, China.
Sadeghizadeh M; Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, P.O. Box: 14115-154, Tehran, Iran. .
Babashah S; Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, P.O. Box: 14115-154, Tehran, Iran. .
Źródło:
Journal of translational medicine [J Transl Med] 2022 Dec 03; Vol. 20 (1), pp. 559. Date of Electronic Publication: 2022 Dec 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: [London] : BioMed Central, 2003-
MeSH Terms:
Breast Neoplasms*/genetics
Breast Neoplasms*/immunology
Cancer-Associated Fibroblasts*/immunology
MicroRNAs*/genetics
MicroRNAs*/immunology
Monocytes*/immunology
Tumor Microenvironment*/genetics
Tumor Microenvironment*/immunology
Animals ; Humans ; Mice ; Macrophages/immunology ; Mice, Nude ; Proto-Oncogene Proteins c-akt/genetics ; Proto-Oncogene Proteins c-akt/immunology ; Reactive Oxygen Species ; Signal Transduction
References:
Immunobiology. 2010 Sep-Oct;215(9-10):737-47. (PMID: 20605053)
Cancer Cell. 2009 Jul 7;16(1):21-32. (PMID: 19573809)
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7564-9. (PMID: 17452630)
Redox Biol. 2019 Apr;22:101116. (PMID: 30769285)
JCI Insight. 2021 Mar 8;6(5):. (PMID: 33539325)
Clin Cancer Res. 2017 Nov 15;23(22):6823-6832. (PMID: 28874413)
Cancers (Basel). 2021 Mar 19;13(6):. (PMID: 33808627)
J Clin Lab Anal. 2020 Feb;34(2):e23063. (PMID: 31595567)
Front Immunol. 2022 Apr 11;13:887380. (PMID: 35479076)
Cell Cycle. 2013 Jun 1;12(11):1679-87. (PMID: 23656790)
Mol Ther. 2022 Oct 5;30(10):3133-3154. (PMID: 35405312)
J Oral Pathol Med. 2012 Jul;41(6):444-51. (PMID: 22296275)
Trends Mol Med. 2018 May;24(5):472-489. (PMID: 29655673)
Blood. 2004 Oct 15;104(8):2224-34. (PMID: 15231578)
J Hematol Oncol. 2015 Jun 11;8:68. (PMID: 26062952)
Mol Ther Nucleic Acids. 2022 May 31;29:16-35. (PMID: 35784014)
J Biomed Sci. 2019 Oct 20;26(1):78. (PMID: 31629410)
Oxid Med Cell Longev. 2016;2016:2795090. (PMID: 27143992)
Signal Transduct Target Ther. 2021 Jul 12;6(1):262. (PMID: 34248141)
Physiol Res. 2016 Dec 21;65(Suppl 4):S441-S453. (PMID: 28006926)
Oncogene. 2014 May 8;33(19):2423-31. (PMID: 23728338)
Front Oncol. 2021 Jul 14;11:668349. (PMID: 34336660)
Signal Transduct Target Ther. 2020 Aug 25;5(1):166. (PMID: 32843638)
Int J Mol Sci. 2021 Jun 29;22(13):. (PMID: 34209703)
Front Immunol. 2018 Mar 01;9:414. (PMID: 29545811)
Cell Oncol (Dordr). 2017 Oct;40(5):457-470. (PMID: 28741069)
Int J Oncol. 2021 Aug;59(2):. (PMID: 34195849)
Med Oncol. 2022 May 16;39(5):83. (PMID: 35570226)
J Cell Commun Signal. 2020 Jun;14(2):233-244. (PMID: 32034654)
PLoS One. 2014 Nov 05;9(11):e111539. (PMID: 25372293)
Nat Med. 2013 Nov;19(11):1423-37. (PMID: 24202395)
Br J Cancer. 2020 Oct;123(9):1353-1355. (PMID: 32830198)
Cell Death Dis. 2019 Mar 20;10(4):273. (PMID: 30894509)
Front Immunol. 2017 Mar 27;8:303. (PMID: 28396660)
Eur J Cancer. 2011 May;47(8):1127-37. (PMID: 21402473)
BMC Med. 2015 Mar 05;13:45. (PMID: 25857315)
J Cancer. 2018 Nov 24;9(24):4635-4641. (PMID: 30588247)
Cancer Cell. 2018 Mar 12;33(3):463-479.e10. (PMID: 29455927)
J Leukoc Biol. 2009 Nov;86(5):1065-73. (PMID: 19741157)
Oncotarget. 2015 Jun 10;6(16):14687-99. (PMID: 26008983)
Sci Rep. 2019 Feb 28;9(1):3172. (PMID: 30816272)
Science. 2020 Feb 7;367(6478):. (PMID: 32029601)
J Exp Clin Cancer Res. 2020 Apr 16;39(1):67. (PMID: 32299469)
J Hematol Oncol. 2019 Aug 28;12(1):86. (PMID: 31462327)
Nat Rev Cancer. 2016 Aug 23;16(9):582-98. (PMID: 27550820)
Curr Biol. 2020 Aug 17;30(16):R921-R925. (PMID: 32810447)
Semin Cancer Biol. 2014 Apr;25:69-77. (PMID: 24406209)
Cancer Cell. 2019 Apr 15;35(4):588-602.e10. (PMID: 30930117)
Mol Cancer. 2021 Oct 11;20(1):131. (PMID: 34635121)
Neuro Oncol. 2017 Oct 19;19(11):1435-1446. (PMID: 28575312)
Curr Biol. 2020 Mar 23;30(6):R246-R248. (PMID: 32208142)
J Hematol Oncol. 2019 Jul 12;12(1):76. (PMID: 31300030)
Int J Mol Sci. 2021 Jul 05;22(13):. (PMID: 34281293)
Mol Cancer Res. 2012 Nov;10(11):1403-18. (PMID: 23024188)
Lab Invest. 2013 Jul;93(7):844-54. (PMID: 23752129)
Int J Oncol. 2011 Apr;38(4):955-62. (PMID: 21271219)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Cancer Med. 2017 Feb;6(2):463-470. (PMID: 28097809)
Clin Transl Oncol. 2020 Dec;22(12):2141-2152. (PMID: 32447645)
Mol Cancer. 2019 Mar 30;18(1):64. (PMID: 30927925)
FEBS Lett. 2014 May 2;588(9):1773-9. (PMID: 24685694)
Int J Mol Sci. 2018 Apr 26;19(5):. (PMID: 29701666)
Front Cell Dev Biol. 2021 Jan 22;8:621070. (PMID: 33553157)
Contributed Indexing:
Keywords: AKT signaling; Breast cancer; Cancer-associated fibroblasts; Exosomes; Immunosuppressive tumor microenvironment; Tumor-associated macrophages
Substance Nomenclature:
0 (MicroRNAs)
0 (MIrn181 microRNA, human)
0 (mirn181 microRNA, mouse)
EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
0 (Reactive Oxygen Species)
EC 2.7.11.1 (AKT1 protein, human)
EC 2.7.11.1 (Akt1 protein, mouse)
Entry Date(s):
Date Created: 20221203 Date Completed: 20221213 Latest Revision: 20221221
Update Code:
20240105
PubMed Central ID:
PMC9719191
DOI:
10.1186/s12967-022-03780-2
PMID:
36463188
Czasopismo naukowe
Background: Cancer-associated fibroblasts (CAFs), one of the major components of the tumor stroma, contribute to an immunosuppressive tumor microenvironment (TME) through the induction and functional polarization of protumoral macrophages. We have herein investigated the contribution of CAFs to monocyte recruitment and macrophage polarization. We also sought to identify a possible paracrine mechanism by which CAF-educated monocytes affect breast cancer (BC) cell progression.
Methods: Monocytes were educated by primary CAFs and normal fibroblast (NF); the phenotypic alterations of CAF- or NF-educated monocytes were measured by flow cytometry. Exosomes isolated from the cultured conditioned media of the educated monocytes were characterized. An in vivo experiment using a subcutaneous transplantation tumor model in athymic nude mice was conducted to uncover the effect of exosomes derived from CAF- or NF-educated monocytes on breast tumor growth. Gain- and loss-of-function experiments were performed to explore the role of miR-181a in BC progression with the involvement of the AKT signaling pathway. Western blotting, enzyme-linked immunosorbent assay, RT-qPCR, flow cytometry staining, migration assay, immunohistochemical staining, and bioinformatics analysis were performed to reveal the underlying mechanisms.
Results: We illustrated that primary CAFs recruited monocytes and established pro-tumoral M2 macrophages. CAF may also differentiate human monocyte THP-1 cells into anti-inflammatory M2 macrophages. Besides, we revealed that CAFs increased reactive oxygen species (ROS) generation in THP-1 monocytes, as differentiating into M2 macrophages requires a level of ROS for proper polarization. Importantly, T-cell proliferation was suppressed by CAF-educated monocytes and their exosomes, resulting in an immunosuppressive TME. Interestingly, CAF-activated, polarized monocytes lost their tumoricidal abilities, and their derived exosomes promoted BC cell proliferation and migration. In turn, CAF-educated monocyte exosomes exhibited a significant promoting effect on BC tumorigenicity in vivo. Of clinical significance, we observed that up-regulation of circulating miR-181a in BC was positively correlated with tumor aggressiveness and found a high level of this miRNA in CAF-educated monocytes and their exosomes. We further clarified that the pro-oncogenic effect of CAF-educated monocytes may depend in part on the exosomal transfer of miR-181a through modulating the PTEN/Akt signaling axis in BC cells.
Conclusions: Our findings established a connection between tumor stromal communication and tumor progression and demonstrated an inductive function for CAF-educated monocytes in BC cell progression. We also proposed a supporting model in which exosomal transfer of miR-181a from CAF-educated monocytes activates AKT signaling by regulating PTEN in BC cells.
(© 2022. The Author(s).)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies